Senti Biosciences Files 8-K
Ticker: SNTI · Form: 8-K · Filed: Dec 16, 2024 · CIK: 1854270
Sentiment: neutral
Topics: 8-K, filing, corporate-event
TL;DR
Senti Bio filed an 8-K, mostly procedural stuff.
AI Summary
On December 16, 2024, Senti Biosciences, Inc. filed an 8-K report. The filing primarily concerns other events and financial statements/exhibits, with no specific material events or financial updates detailed in the provided text.
Why It Matters
This filing indicates Senti Biosciences is submitting required documentation to the SEC, which could include updates on corporate events or financial information.
Risk Assessment
Risk Level: low — The filing is a routine 8-K submission without immediate disclosure of significant negative or positive events.
Key Players & Entities
- Senti Biosciences, Inc. (company) — Registrant
- December 16, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-40440 (identifier) — Commission File Number
- 86-2437900 (identifier) — IRS Employer Identification No.
- 2 Corporate Drive, First Floor (address) — Principal executive offices
- South San Francisco (location) — City of principal executive offices
- CA (state) — State of principal executive offices
- 94080 (zip_code) — Zip code of principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Senti Biosciences, Inc.?
The filing is primarily for 'Other Events' and 'Financial Statements and Exhibits', indicating routine corporate reporting.
When was the earliest event reported in this filing?
The earliest event reported is dated December 16, 2024.
In which state is Senti Biosciences, Inc. incorporated?
Senti Biosciences, Inc. is incorporated in Delaware.
What is the Commission File Number for Senti Biosciences, Inc.?
The Commission File Number is 001-40440.
What is the business address of Senti Biosciences, Inc.?
The business address is 2 Corporate Drive, First Floor, South San Francisco, California 94080.
Filing Stats: 506 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-12-16 16:09:26
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share SNTI The Nasdaq Capital Marke
Filing Documents
- snti-20241216.htm (8-K) — 27KB
- a202412168kex991celestpr.htm (EX-99.1) — 20KB
- senti_logoxpr.jpg (GRAPHIC) — 3KB
- 0001854270-24-000128.txt ( ) — 184KB
- snti-20241216.xsd (EX-101.SCH) — 2KB
- snti-20241216_lab.xml (EX-101.LAB) — 22KB
- snti-20241216_pre.xml (EX-101.PRE) — 13KB
- snti-20241216_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events On December 16, 2024, Senti Biosciences, Inc. (the "Company") issued a press release announcing the first patient dosed in a clinical trial of SN301A in hepatocellular carcinoma in collaboration with Celest Therapeutics (Shanghai) Co. Ltd. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 8.01 of Form 8-K and Exhibit 99.1 attached hereto is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated December 16, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SENTI BIOSCIENCES, INC. Date: December 16, 2024 By: /s/ Timothy Lu Name: Timothy Lu, M.D., Ph.D. Title: Chief Executive Officer